CY1114733T1 - Παραγοντες απεικονισης που στοχευουν βιταμινες - Google Patents
Παραγοντες απεικονισης που στοχευουν βιταμινεςInfo
- Publication number
- CY1114733T1 CY1114733T1 CY20131101164T CY131101164T CY1114733T1 CY 1114733 T1 CY1114733 T1 CY 1114733T1 CY 20131101164 T CY20131101164 T CY 20131101164T CY 131101164 T CY131101164 T CY 131101164T CY 1114733 T1 CY1114733 T1 CY 1114733T1
- Authority
- CY
- Cyprus
- Prior art keywords
- vitamins
- imaging agents
- agents targeting
- targeting
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/025—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus inorganic Tc complexes or compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει τη χρήση μιας ένωσης του χημικού τύπου όπου το V είναι ένα μόριο φυλλικού, όπου το φυλλικό είναι ένα υπόστρωμα για την διαμεσολαβούμενη από υποδοχέα διαμεμβρανική μεταφορά in vivo, ή ένα παράγωγο του φυλλικού που συνδέεται στον υποδοχέα ή ένα ανάλογο αυτών, το L είναι ένα δισθενές συνδετικό μόριο, το R είναι μια πλευρική αλυσίδα ενός αμινοξέος, τo M είναι ένα κατιόν ενός ραδιονουκλεϊδίου, το n είναι 1 ή 0 το k είναι 1 ή 0 για την απεικόνιση ενός πληθυσμού κυττάρων σε ένα ζώο στο οποίο έχει προηγηθεί έγχυση με μη ιχνηθετημένο φυλλικό. Παρέχεται επίσης ο συνδυασμός της ένωσης με ιχνηθετημένο φυλλικό.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37857102P | 2002-05-06 | 2002-05-06 | |
EP09171503.7A EP2151250B1 (en) | 2002-05-06 | 2003-05-06 | Vitamin-Targeted imaging agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114733T1 true CY1114733T1 (el) | 2016-12-14 |
Family
ID=29401611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101164T CY1114733T1 (el) | 2002-05-06 | 2013-12-27 | Παραγοντες απεικονισης που στοχευουν βιταμινες |
Country Status (19)
Country | Link |
---|---|
US (5) | US7128893B2 (el) |
EP (4) | EP2258401B1 (el) |
JP (1) | JP4801348B2 (el) |
KR (1) | KR100978418B1 (el) |
CN (2) | CN100528241C (el) |
AT (1) | ATE448799T1 (el) |
AU (1) | AU2003239383C1 (el) |
CA (1) | CA2484345C (el) |
CY (1) | CY1114733T1 (el) |
DE (1) | DE60330135D1 (el) |
DK (3) | DK2260875T3 (el) |
ES (4) | ES2500922T3 (el) |
HK (1) | HK1141440A1 (el) |
IL (1) | IL164811A (el) |
NZ (1) | NZ536467A (el) |
PT (2) | PT2151250E (el) |
SI (2) | SI2151250T1 (el) |
WO (1) | WO2003092742A1 (el) |
ZA (1) | ZA200408664B (el) |
Families Citing this family (94)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60231868D1 (de) | 2001-04-24 | 2009-05-20 | Purdue Research Foundation | Folat-mimetika und deren folatrezeptorbindende konjugate |
EP1390077B1 (en) | 2001-05-02 | 2014-07-16 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
US8043603B2 (en) * | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
EP2258401B1 (en) * | 2002-05-06 | 2014-07-09 | Endocyte, Inc. | Folate-receptor targeted imaging agents |
AU2003243226A1 (en) * | 2002-05-15 | 2003-12-02 | Endocyte, Inc. | Vitamin-mitomycin conjugates |
EP2529758A3 (en) | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
JP2007526238A (ja) * | 2003-05-06 | 2007-09-13 | パーデュー・リサーチ・ファウンデーション | マクロファージまたは葉酸受容体を標的とする狼瘡治療法 |
WO2004110250A2 (en) | 2003-05-30 | 2004-12-23 | Purdue Research Foundation | Diagnostic method for atherosclerosis |
WO2006012527A1 (en) | 2004-07-23 | 2006-02-02 | Endocyte, Inc. | Bivalent linkers and conjugates thereof |
CA2587779A1 (en) * | 2004-11-10 | 2007-01-18 | University Of South Florida | Platinum complexes for targeted drug delivery |
CN101128152A (zh) * | 2004-12-23 | 2008-02-20 | 普渡研究基金会 | 发射正电子段层成像方法 |
US8044200B2 (en) * | 2005-03-16 | 2011-10-25 | Endocyte, Inc. | Synthesis and purification of pteroic acid and conjugates thereof |
JP5175723B2 (ja) * | 2005-07-05 | 2013-04-03 | パーデュー・リサーチ・ファウンデーション | 単球介在性疾患を治療するための組成物の調製 |
EP2382995A3 (en) | 2005-08-19 | 2013-09-25 | Endocyte, Inc. | Ligand conjugates of Vinca alkaloids, analogs and derivatives |
CN103893779A (zh) | 2005-08-19 | 2014-07-02 | 恩多塞特公司 | 多药物配体缀合物 |
WO2007038346A2 (en) | 2005-09-23 | 2007-04-05 | Purdue Research Foundation | Multiphoton in vivo flow cytometry method and device |
CA2668197A1 (en) * | 2006-11-03 | 2008-05-15 | Philip S. Low | Ex vivo flow cytometry method and device |
WO2008098112A2 (en) * | 2007-02-07 | 2008-08-14 | Purdue Research Foundation | Positron emission tomography imaging method |
WO2008101231A2 (en) | 2007-02-16 | 2008-08-21 | Endocyte, Inc. | Methods and compositions for treating and diagnosing kidney disease |
EP2604284A1 (en) * | 2007-02-16 | 2013-06-19 | KTB Tumorforschungsgesellschaft mbH | Receptor And Antigen Targeted Prodrug |
CA2680535C (en) | 2007-03-14 | 2016-09-20 | Endocyte, Inc. | Binding ligand linked drug delivery conjugates of tubulysins |
EP2146944B1 (en) | 2007-04-11 | 2014-01-22 | Merck & Cie | A method for the preparation of 18f-labelled folates |
CA2670385C (en) * | 2007-04-11 | 2016-01-12 | Merck Eprova Ag | Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy |
EP2164525A2 (en) * | 2007-05-25 | 2010-03-24 | Purdue Research Foundation | Method of imaging localized infections |
WO2009002993A1 (en) | 2007-06-25 | 2008-12-31 | Endocyte, Inc. | Conjugates containing hydrophilic spacer linkers |
US9877965B2 (en) | 2007-06-25 | 2018-01-30 | Endocyte, Inc. | Vitamin receptor drug delivery conjugates for treating inflammation |
PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
AU2008316835B2 (en) | 2007-10-25 | 2015-07-16 | Endocyte, Inc. | Tubulysins and processes for preparing |
EP2222328A4 (en) * | 2007-11-15 | 2013-06-05 | Endocyte Inc | PROCESS FOR THE ADMINISTRATION OF CONJUGATES |
US9332973B2 (en) | 2008-10-01 | 2016-05-10 | Covidien Lp | Needle biopsy device with exchangeable needle and integrated needle protection |
US9782565B2 (en) | 2008-10-01 | 2017-10-10 | Covidien Lp | Endoscopic ultrasound-guided biliary access system |
US8968210B2 (en) | 2008-10-01 | 2015-03-03 | Covidien LLP | Device for needle biopsy with integrated needle protection |
US11298113B2 (en) | 2008-10-01 | 2022-04-12 | Covidien Lp | Device for needle biopsy with integrated needle protection |
US9186128B2 (en) | 2008-10-01 | 2015-11-17 | Covidien Lp | Needle biopsy device |
WO2010083104A2 (en) | 2009-01-13 | 2010-07-22 | Emory University | Conjugates of noscapine and folic acid and their use in treating cancer |
US8975389B2 (en) | 2009-03-02 | 2015-03-10 | Alnylam Pharmaceuticals, Inc. | Nucleic acid chemical modifications |
EP2403412A4 (en) * | 2009-03-05 | 2013-08-07 | Purdue Research Foundation | PROCESS FOR EARLY IMAGING OF ATHEROSCLEROSIS |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
PL2556171T3 (pl) | 2010-04-05 | 2016-04-29 | Prognosys Biosciences Inc | Oznaczenia biologiczne kodowane przestrzennie |
US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
WO2011130716A2 (en) | 2010-04-16 | 2011-10-20 | Access Pharmaceuticals, Inc. | A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers |
US10913767B2 (en) | 2010-04-22 | 2021-02-09 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising acyclic and abasic nucleosides and analogs |
US20130260460A1 (en) | 2010-04-22 | 2013-10-03 | Isis Pharmaceuticals Inc | Conformationally restricted dinucleotide monomers and oligonucleotides |
KR20140026396A (ko) | 2011-03-08 | 2014-03-05 | 어섹스 팔마큐티칼스 인코포레이티드 | 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템 |
GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
KR102036199B1 (ko) | 2011-08-17 | 2019-10-24 | 메르크 앤드 씨에 | 알부민-결합 개체들의 폴레이트 공액체들 |
EP2800586A1 (en) | 2012-01-03 | 2014-11-12 | Invictus Oncology Pvt. Ltd. | Ligand-targeted molecules and methods thereof |
WO2013126797A1 (en) | 2012-02-24 | 2013-08-29 | Purdue Research Foundation | Cholecystokinin b receptor targeting for imaging and therapy |
US9629918B2 (en) | 2012-02-29 | 2017-04-25 | Purdue Research Foundation | Folate receptor alpha binding ligands |
US20140080175A1 (en) | 2012-03-29 | 2014-03-20 | Endocyte, Inc. | Processes for preparing tubulysin derivatives and conjugates thereof |
US20150174273A1 (en) * | 2012-07-25 | 2015-06-25 | Emory University | Imaging and therapeutic methods for treating parathyroid tumors |
WO2014062697A2 (en) | 2012-10-16 | 2014-04-24 | Endocyte, Inc. | Drug delivery conjugates containing unnatural amino acids and methods for using |
KR101551232B1 (ko) | 2012-10-26 | 2015-09-10 | 한국원자력연구원 | N3s1형의 새로운 킬레이터가 접합된 폴레이트 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암 진단 또는 치료용 조성물 |
KR102499944B1 (ko) | 2012-11-15 | 2023-02-14 | 엔도사이트, 인코포레이티드 | Psma 발현 세포에 의해 야기되는 질병을 치료하기 위한 컨쥬게이트 |
WO2014150943A1 (en) * | 2013-03-15 | 2014-09-25 | Purdue Research Foundation | Asthma imaging and therapy |
CN118240918A (zh) | 2013-06-25 | 2024-06-25 | 普罗格诺西斯生物科学公司 | 采用微流控装置的空间编码生物分析 |
EP4374924A2 (en) | 2013-10-18 | 2024-05-29 | Novartis AG | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
AU2014348601A1 (en) * | 2013-11-14 | 2016-05-26 | Endocyte, Inc. | Compounds for positron emission tomography |
EP3865153A1 (en) | 2013-11-19 | 2021-08-18 | Purdue Research Foundation | Patient selection method for inflammation |
WO2015153345A1 (en) | 2014-04-03 | 2015-10-08 | Invictus Oncology Pvt. Ltd. | Supramolecular combinatorial therapeutics |
WO2015200187A1 (en) * | 2014-06-27 | 2015-12-30 | Reiley Pharmaceuticals, Inc. | Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging |
US20160166679A1 (en) * | 2014-12-12 | 2016-06-16 | Purdue Research Foundation | Method of treatment using folate conjugates and tyrosine kinase inhibitors |
JP2018504380A (ja) | 2014-12-18 | 2018-02-15 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Reversir(商標)化合物 |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
EP3242688B1 (en) | 2015-01-09 | 2020-01-29 | Reiley Pharmaceuticals, Inc. | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers |
EP4119677B1 (en) | 2015-04-10 | 2023-06-28 | Spatial Transcriptomics AB | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
CA2989970A1 (en) | 2015-07-17 | 2017-01-26 | Alnylam Pharmaceuticals, Inc. | Multi-targeted single entity conjugates |
WO2017030893A1 (en) * | 2015-08-14 | 2017-02-23 | Endocyte, Inc. | Method of imaging with a chelating compound |
ES2926495T3 (es) | 2015-12-04 | 2022-10-26 | 10X Genomics Inc | Métodos y composiciones para el análisis de ácidos nucleicos |
US10857234B2 (en) | 2016-03-16 | 2020-12-08 | Endocyte Inc. | Carbonic anhydrase IX inhibitor conjugates and uses thereof |
JP7027325B2 (ja) | 2016-03-16 | 2022-03-01 | パーデュー・リサーチ・ファウンデイション | 炭酸無水酵素ixを標的とする薬剤および方法 |
US20170296679A1 (en) | 2016-04-18 | 2017-10-19 | Intuitive Surgical Operations, Inc. | Compositions of Near IR Closed Chain, Sulfo-Cyanine Dyes and Prostate Specific Membrane Antigen Ligands |
WO2019040474A1 (en) | 2017-08-22 | 2019-02-28 | Purdue Research Foundation | THERAPEUTIC AND RADIOIMAGING CONJUGATES BASED ON FBSA TARGETING POSITIVE CANCERS FOR CARBONIC ANHYDRASE |
MX2020011570A (es) | 2018-05-07 | 2020-11-24 | Alnylam Pharmaceuticals Inc | Administracion extrahepatica. |
TW202028465A (zh) | 2018-09-28 | 2020-08-01 | 美商阿尼拉製藥公司 | 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法 |
JP2022532652A (ja) | 2019-05-17 | 2022-07-15 | アルニラム ファーマスーティカルズ インコーポレイテッド | オリゴヌクレオチドの経口送達 |
WO2021086982A2 (en) | 2019-10-28 | 2021-05-06 | Beckman Coulter, Inc. | Compounds for the identification of microbial classes and uses thereof |
EP4055165A1 (en) | 2019-11-06 | 2022-09-14 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases |
KR20220110749A (ko) | 2019-11-06 | 2022-08-09 | 알닐람 파마슈티칼스 인코포레이티드 | 간외 전달 |
WO2021252499A1 (en) | 2020-06-08 | 2021-12-16 | 10X Genomics, Inc. | Methods of determining a surgical margin and methods of use thereof |
US11981960B1 (en) | 2020-07-06 | 2024-05-14 | 10X Genomics, Inc. | Spatial analysis utilizing degradable hydrogels |
US20230257745A1 (en) | 2020-07-10 | 2023-08-17 | Alnylam Pharmaceuticals, Inc. | Circular siRNAs |
CN116916968A (zh) | 2020-10-30 | 2023-10-20 | 托德·斯皮尔 | 基于寡核苷酸的治疗剂及其用途 |
EP4271696A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
EP4271695A2 (en) | 2020-12-31 | 2023-11-08 | Alnylam Pharmaceuticals, Inc. | 2'-modified nucleoside based oligonucleotide prodrugs |
WO2022150721A1 (en) * | 2021-01-08 | 2022-07-14 | Lycia Therapeutics, Inc. | Bifunctional folate receptor binding compounds |
WO2023283403A2 (en) | 2021-07-09 | 2023-01-12 | Alnylam Pharmaceuticals, Inc. | Bis-rnai compounds for cns delivery |
WO2023003922A1 (en) | 2021-07-21 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Metabolic disorder-associated target gene irna compositions and methods of use thereof |
CA3234887A1 (en) | 2021-10-15 | 2023-04-20 | Alnylam Pharmaceuticals, Inc. | Extra-hepatic delivery irna compositions and methods of use thereof |
WO2023220744A2 (en) | 2022-05-13 | 2023-11-16 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
WO2024006999A2 (en) | 2022-06-30 | 2024-01-04 | Alnylam Pharmaceuticals, Inc. | Cyclic-disulfide modified phosphate based oligonucleotide prodrugs |
WO2024073732A1 (en) | 2022-09-30 | 2024-04-04 | Alnylam Pharmaceuticals, Inc. | Modified double-stranded rna agents |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2816110A (en) | 1956-11-23 | 1957-12-10 | Merck & Co Inc | Methods for the production of substituted pteridines |
US5140104A (en) | 1982-03-09 | 1992-08-18 | Cytogen Corporation | Amine derivatives of folic acid analogs |
US5175343A (en) * | 1985-01-14 | 1992-12-29 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
US5242679A (en) * | 1985-01-14 | 1993-09-07 | Neorx Corporation | Metal radionuclide labeled proteins for diagnosis and therapy |
NZ217821A (en) | 1985-10-10 | 1989-07-27 | Biotech Australia Pty Ltd | Oral delivery system; complex of active agent and vitamin b12 or analogue thereof |
GB8608335D0 (en) | 1986-04-04 | 1986-05-08 | Pfizer Ltd | Pharmaceutically acceptable salts |
EP0273085A1 (en) | 1986-12-29 | 1988-07-06 | IntraCel Corporation | A method for internalizing nucleic acids into eukaryotic cells |
US5053493A (en) * | 1987-04-02 | 1991-10-01 | Centocor Cardiovascular Imaging Partners, L.P. | Method for labeling antibodies with a metal ion |
US5688488A (en) * | 1989-04-03 | 1997-11-18 | Purdue Research Foundation | Composition and method for tumor imaging |
US7238340B1 (en) * | 1991-11-27 | 2007-07-03 | Cis Bio International | Monoamine, diamide, thiol-containing metal chelating agents |
ES2141102T3 (es) * | 1991-02-08 | 2000-03-16 | Diatide Inc | Polipeptidos marcados con tecnecio-99m para la generacion de imagenes. |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US5159079A (en) | 1991-12-20 | 1992-10-27 | Eli Lilly And Company | 2-piperidones as intermediates for 5-deaza-10-oxo- and 5-deaza-10-thio-5,6,7,8-tetrahydrofolic acids |
US6022966A (en) | 1993-11-22 | 2000-02-08 | Neorx Corporation | Pretargeting methods and compounds |
DE4311021A1 (de) * | 1993-03-31 | 1994-10-27 | Diagnostikforschung Inst | Bifunktionelle Chelatbildner, deren Technetium- und Rhenium-Komplexe, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende radiopharmazeutische Mittel |
DE4311023C2 (de) * | 1993-03-31 | 1996-05-02 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner von Typ XN¶1¶S¶1¶O¶1¶ für radioaktive Isotope, deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4311022C2 (de) * | 1993-03-31 | 1996-07-11 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ S¶3¶N¶2¶ für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4310999C2 (de) * | 1993-03-31 | 1996-07-18 | Diagnostikforschung Inst | Bifunktionelle chalkogenatom-unterbrochene Chelatbildner vom Typ XN¶1¶S¶1¶X' für radioaktive Isotope und deren Metallkomplexe, Verfahren zu ihrer Herstellung sowie diese enthaltende pharmazeutische Mittel |
DE4425781A1 (de) * | 1994-07-14 | 1996-01-18 | Schering Ag | Technetium-Sulfonamid-Komplexe, deren Verwendung, diese enthaltende pharmazeutische Mittel, sowie Verfahren zur Herstellung der Komplexe und Mittel |
US6083480A (en) * | 1997-05-01 | 2000-07-04 | Diatide, Inc. | Calcitonin receptor binding reagents |
US6093382A (en) * | 1998-05-16 | 2000-07-25 | Bracco Research Usa Inc. | Metal complexes derivatized with folate for use in diagnostic and therapeutic applications |
US6323313B1 (en) * | 1999-06-01 | 2001-11-27 | The University Of Washington | Annexin derivative with endogenous chelation sites |
EP1286704B1 (en) * | 2000-06-02 | 2014-07-23 | Board of Regents, The University of Texas System | ETHYLENEDICYSTEINE (EC)-glucose analog CONJUGATES |
EP1390077B1 (en) | 2001-05-02 | 2014-07-16 | Purdue Research Foundation | Treatment and diagnosis of macrophage mediated disease |
EP2258401B1 (en) | 2002-05-06 | 2014-07-09 | Endocyte, Inc. | Folate-receptor targeted imaging agents |
EP2529758A3 (en) * | 2003-01-27 | 2013-01-02 | Endocyte, Inc. | Vitamin receptor binding drug delivery conjugates |
JP2007526238A (ja) * | 2003-05-06 | 2007-09-13 | パーデュー・リサーチ・ファウンデーション | マクロファージまたは葉酸受容体を標的とする狼瘡治療法 |
-
2003
- 2003-05-06 EP EP10179448.5A patent/EP2258401B1/en not_active Expired - Lifetime
- 2003-05-06 CA CA2484345A patent/CA2484345C/en not_active Expired - Fee Related
- 2003-05-06 EP EP03733967A patent/EP1501551B1/en not_active Expired - Lifetime
- 2003-05-06 ES ES10179448.5T patent/ES2500922T3/es not_active Expired - Lifetime
- 2003-05-06 DK DK10179508.6T patent/DK2260875T3/da active
- 2003-05-06 CN CNB038146835A patent/CN100528241C/zh not_active Expired - Fee Related
- 2003-05-06 ES ES09171503.7T patent/ES2438008T3/es not_active Expired - Lifetime
- 2003-05-06 DK DK09171503.7T patent/DK2151250T3/da active
- 2003-05-06 AU AU2003239383A patent/AU2003239383C1/en not_active Ceased
- 2003-05-06 DE DE60330135T patent/DE60330135D1/de not_active Expired - Lifetime
- 2003-05-06 ES ES10179508.6T patent/ES2472423T3/es not_active Expired - Lifetime
- 2003-05-06 AT AT03733967T patent/ATE448799T1/de not_active IP Right Cessation
- 2003-05-06 EP EP09171503.7A patent/EP2151250B1/en not_active Expired - Lifetime
- 2003-05-06 KR KR1020047017608A patent/KR100978418B1/ko active IP Right Grant
- 2003-05-06 EP EP10179508.6A patent/EP2260875B1/en not_active Expired - Lifetime
- 2003-05-06 DK DK10179448.5T patent/DK2258401T3/da active
- 2003-05-06 WO PCT/US2003/014379 patent/WO2003092742A1/en active Application Filing
- 2003-05-06 PT PT91715037T patent/PT2151250E/pt unknown
- 2003-05-06 US US10/430,519 patent/US7128893B2/en not_active Expired - Lifetime
- 2003-05-06 NZ NZ536467A patent/NZ536467A/en not_active IP Right Cessation
- 2003-05-06 JP JP2004500925A patent/JP4801348B2/ja not_active Expired - Fee Related
- 2003-05-06 CN CN200910151274XA patent/CN101648028B/zh not_active Expired - Fee Related
- 2003-05-06 SI SI200332331T patent/SI2151250T1/sl unknown
- 2003-05-06 SI SI200332355T patent/SI2260875T1/sl unknown
- 2003-05-06 ES ES03733967T patent/ES2336780T3/es not_active Expired - Lifetime
- 2003-05-06 PT PT101795086T patent/PT2260875E/pt unknown
-
2004
- 2004-10-25 IL IL164811A patent/IL164811A/en active IP Right Grant
- 2004-10-26 ZA ZA200408664A patent/ZA200408664B/en unknown
-
2006
- 2006-10-11 US US11/546,099 patent/US7862798B2/en not_active Expired - Fee Related
-
2009
- 2009-09-11 US US12/558,163 patent/US8313728B2/en not_active Expired - Lifetime
-
2010
- 2010-08-16 HK HK10107801.2A patent/HK1141440A1/xx not_active IP Right Cessation
-
2012
- 2012-10-18 US US13/654,527 patent/US8865126B2/en not_active Expired - Fee Related
-
2013
- 2013-03-11 US US13/793,624 patent/US8834842B2/en not_active Expired - Fee Related
- 2013-12-27 CY CY20131101164T patent/CY1114733T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114733T1 (el) | Παραγοντες απεικονισης που στοχευουν βιταμινες | |
BR0307924A (pt) | N-aril-2-oxazolidinona-5-carboxamidas e seus derivados | |
DZ3420A1 (fr) | Combinaison d'herbicides avec des sulfonylurees speciales | |
DE69907977D1 (de) | Pyrrolobenzodiazepine | |
DE60230163D1 (de) | Sicherheitsgurt-vorspannvorrichtung | |
DE60112974D1 (en) | Carbolinderivate | |
CY1108738T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου | |
DE60229736D1 (de) | Spiroinden- und spiroindan-verbindungen | |
DE60215179D1 (de) | Dolastatin 10 derivate | |
DE60222044D1 (de) | Nitrid-Feldeffekttransistor | |
BG108269A (en) | Pyrazolopyrimidines as therapeutic agents | |
DK1414828T3 (da) | Antitumoranaloger | |
DE60216233D1 (en) | Carbolinderivate | |
ITMI20011306A0 (it) | Poliuretani vulcanizzabili | |
BRPI0413744A (pt) | n-aril-2-ciano-oxazolidinonas e seus derivados | |
BRPI0409143A (pt) | n-aril-2-oxazolidinona-5-carboxamidas e seus derivados | |
YU83903A (sh) | Farmaceutske kombinacije zasnovane na derivatima piridoindolona | |
ATE321760T1 (de) | N-aryl-2-oxazolidinone und deren derivate | |
BRPI0415428A (pt) | formulações terapêuticas | |
ATE377608T1 (de) | Hemoglobin konjugate | |
ATE478155T1 (de) | Glycopeptidantibiotika | |
ES1048879Y (es) | Accesorio vertical de sulfatado sobre tractor. | |
UY28151A1 (es) | Derivados de 1,2,4-triaminobenceno | |
ATE295117T1 (de) | Medizinische bandelektrode | |
UA6121S (uk) | Емблема «джерело» |